ArticleBMC biotechnology2026
A novel cell-penetrating peptide supports hair follicle growth through anti-inflammatory and growth factor-associated mechanisms in preclinical models.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Translational Assessment of a Cell-Penetrating Peptide Topical Formulation for Repairing Barrier Dysfunction in Human Skin.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHair loss remains a prevalent condition for both men and women worldwide. Current therapies for this condition, including minoxidil and finasteride, are limited by inconsistent efficacy, side effects, and dependence on continuous use. Cell-penetrating peptides (CPPs) have emerged as promising bioactive agents in dermatology due to their ability to traverse cell membranes and modulate multiple biological pathways relevant to hair regeneration.
objectiveThis study aimed to identify and evaluate a novel synthetic CPP, DualPep-ALO, for its potential to promote hair growth by restoring the follicular microenvironment and stimulating key regenerative pathways.
methodsUsing the intra-dermal delivery technology platform (REMEDI), over 200 human protein-derived peptides were screened for cell-penetrating potential. The lead candidate, DualPep-ALO, was selected based on its proliferative effect on human follicle dermal papilla cells and upregulation of Wnt/β-catenin and ERK signaling. In vitro and ex vivo assays were conducted to assess antioxidant enzyme activity, inflammatory cytokine suppression, follicle elongation, anagen maintenance, and growth factor expression.
resultsDualPep-ALO significantly enhanced human follicle dermal papilla cell proliferation, restored antioxidant enzyme (SOD, CAT) activity, and suppressed pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, PGE-2). In ex vivo human scalp tissue, it promoted hair follicle elongation, maintained the anagen phase, and upregulated VEGF, HGF, and EGF expression, achieving outcomes comparable to minoxidil.
conclusionDualPep-ALO demonstrates potent antioxidant, anti-inflammatory, and pro-regenerative effects, restoring follicular vitality through multimodal biological pathways. These findings support its potential as a novel CPP-based topical agent for hair loss, warranting further clinical investigation to validate efficacy, safety, and long-term therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.